Adrenoleukodystrophy Drugs Market in South Korea - Manufacturing and Consumption, Outlook and Forecast 2020-2026

April 2020 | 90 pages | ID: AEDD16B5CB11EN
Market Monitor Global

Abstracts

Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).
Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.
There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.

This report contains market size and forecasts of Adrenoleukodystrophy Drugs in South Korea, including the following market information:
South Korea Adrenoleukodystrophy Drugs Market Revenue, 2015-2020, 2021-2026, ($ millions)
South Korea Adrenoleukodystrophy Drugs Market Consumption, 2015-2020, 2021-2026, (K Units)
South Korea Adrenoleukodystrophy Drugs Production Capacity, 2015-2020, 2021-2026, (K Units)
Top Five Competitors in South Korea Adrenoleukodystrophy Drugs Market 2019 (%)
The global Adrenoleukodystrophy Drugs market was valued at 258.8 million in 2019 and is projected to reach US$ 456 million by 2026, at a CAGR of 15.2% during the forecast period. While the Adrenoleukodystrophy Drugs market size in South Korea was US$ XX million in 2019, and it is expected to reach US$ XX million by the end of 2026, with a CAGR of XX% during 2020-2026.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adrenoleukodystrophy Drugs manufacturers, suppliers, distributors and industry experts on the impacts of the COVID-19 pandemic on businesses, with top challenges including ingredients and raw material delays, component and packaging shortages, reduced/cancelled orders from clients and consumers, and closures of production lines in some impacted areas.
This report also analyses and evaluates the COVID-19 impact on Adrenoleukodystrophy Drugs production and consumption in South Korea

Total Market by Segment:

South Korea Adrenoleukodystrophy Drugs Market, By Type, 2015-2020, 2021-2026 ($ millions) & (K Units)
South Korea Adrenoleukodystrophy Drugs Market Segment Percentages, By Type, 2019 (%)

• Hormone Replacement
• Transplant
• Others

South Korea Adrenoleukodystrophy Drugs Market, By Application, 2015-2020, 2021-2026 ($ millions) & (K Units)
South Korea Adrenoleukodystrophy Drugs Market Segment Percentages, By Application, 2019 (%)

• Childhood Cerebral ALD
• Adrenomyeloneuropathy (AMN)
• Addison-only
• Others

Competitor Analysis

The report also provides analysis of leading market participants including:
Total Adrenoleukodystrophy Drugs Market Competitors Revenues in South Korea, by Players 2015-2020 (Estimated), ($ millions)
Total Adrenoleukodystrophy Drugs Market Competitors Revenues Share in South Korea, by Players 2019 (%)
Total South Korea Adrenoleukodystrophy Drugs Market Competitors Sales, by Players 2015-2020 (Estimated), (K Units)
Total South Korea Adrenoleukodystrophy Drugs Market Competitors Sales Market Share by Players 2019 ($ millions)

Further, the report presents profiles of competitors in the market, including the following:

• Bluebird Bio Inc
• NeuroVia, Inc.
• Orpheris, Inc.
• Minoryx

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Adrenoleukodystrophy Drugs Market Definition
1.2 Market Segments
  1.2.1 Segment by Type
  1.2.2 Segment by Application
1.3 South Korea Adrenoleukodystrophy Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 COVID-19 IMPACT: SOUTH KOREA ADRENOLEUKODYSTROPHY DRUGS OVERALL MARKET SIZE

2.1 South Korea Adrenoleukodystrophy Drugs Market Size: 2020 VS 2026
2.2 South Korea Adrenoleukodystrophy Drugs Revenue, Prospects & Forecasts: 2015-2026
2.3 South Korea Adrenoleukodystrophy Drugs Sales (Consumption): 2015-2026

3 COMPANY LANDSCAPE

3.1 Top Adrenoleukodystrophy Drugs Players in South Korea (including Foreign and Local Companies)
3.2 Top South Korea Adrenoleukodystrophy Drugs Companies Ranked by Revenue
3.3 South Korea Adrenoleukodystrophy Drugs Revenue by Companies (including Foreign and Local Companies)
3.4 South Korea Adrenoleukodystrophy Drugs Sales by Companies (including Foreign and Local Companies)
3.5 South Korea Adrenoleukodystrophy Drugs Price by Manufacturer (2015-2020)
3.6 Top 3 and Top 5 Adrenoleukodystrophy Drugs Companies in South Korea, by Revenue in 2019
3.7 South Korea Manufacturers Adrenoleukodystrophy Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Players in South Korea
  3.8.1 List of South Korea Tier 1 Adrenoleukodystrophy Drugs Companies
  3.8.2 List of South Korea Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Companies

4 SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - South Korea Adrenoleukodystrophy Drugs Market Size Markets, 2020 & 2026
  4.1.2 Hormone Replacement
  4.1.3 Transplant
  4.1.4 Others
4.2 By Type - South Korea Adrenoleukodystrophy Drugs Revenue & Forecasts
  4.2.1 By Type - South Korea Adrenoleukodystrophy Drugs Revenue, 2015-2020
  4.2.2 By Type - South Korea Adrenoleukodystrophy Drugs Revenue, 2021-2026
  4.2.3 By Type - South Korea Adrenoleukodystrophy Drugs Revenue Market Share, 2015-2026
4.3 By Type - South Korea Adrenoleukodystrophy Drugs Sales & Forecasts
  4.3.1 By Type - South Korea Adrenoleukodystrophy Drugs Sales, 2015-2020
  4.3.2 By Type - South Korea Adrenoleukodystrophy Drugs Sales, 2021-2026
  4.3.3 By Type - South Korea Adrenoleukodystrophy Drugs Sales Market Share, 2015-2026
4.4 By Type - South Korea Adrenoleukodystrophy Drugs Price (Manufacturers Selling Prices), 2015-2026

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - South Korea Adrenoleukodystrophy Drugs Market Size, 2020 & 2026
  5.1.2 Childhood Cerebral ALD
  5.1.3 Adrenomyeloneuropathy (AMN)
  5.1.4 Addison-only
  5.1.5 Others
5.2 By Application - South Korea Adrenoleukodystrophy Drugs Revenue & Forecasts
  5.2.1 By Application - South Korea Adrenoleukodystrophy Drugs Revenue, 2015-2020
  5.2.2 By Application - South Korea Adrenoleukodystrophy Drugs Revenue, 2021-2026
  5.2.3 By Application - South Korea Adrenoleukodystrophy Drugs Revenue Market Share, 2015-2026
5.3 By Application - South Korea Adrenoleukodystrophy Drugs Sales & Forecasts
  5.3.1 By Application - South Korea Adrenoleukodystrophy Drugs Sales, 2015-2020
  5.3.2 By Application - South Korea Adrenoleukodystrophy Drugs Sales, 2021-2026
  5.3.3 By Application - South Korea Adrenoleukodystrophy Drugs Sales Market Share, 2015-2026
5.4 By Application - South Korea Adrenoleukodystrophy Drugs Price (Manufacturers Selling Prices), 2015-2026

6 MANUFACTURERS & BRANDS PROFILES

6.1 Bluebird Bio Inc
  6.1.1 Bluebird Bio Inc Corporate Summary
  6.1.2 Bluebird Bio Inc Business Overview
  6.1.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Major Product Offerings
  6.1.4 Bluebird Bio Inc Sales and Revenue in South Korea (2015-2020)
  6.1.5 Bluebird Bio Inc Key News
6.2 NeuroVia, Inc.
  6.2.1 NeuroVia, Inc. Corporate Summary
  6.2.2 NeuroVia, Inc. Business Overview
  6.2.3 NeuroVia, Inc. Adrenoleukodystrophy Drugs Major Product Offerings
  6.2.4 NeuroVia, Inc. Sales and Revenue in South Korea (2015-2020)
  6.2.5 NeuroVia, Inc. Key News
6.3 Orpheris, Inc.
  6.3.1 Orpheris, Inc. Corporate Summary
  6.3.2 Orpheris, Inc. Business Overview
  6.3.3 Orpheris, Inc. Adrenoleukodystrophy Drugs Major Product Offerings
  6.3.4 Orpheris, Inc. Sales and Revenue in South Korea (2015-2020)
  6.3.5 Orpheris, Inc. Key News
6.4 Minoryx
  6.4.1 Minoryx Corporate Summary
  6.4.2 Minoryx Business Overview
  6.4.3 Minoryx Adrenoleukodystrophy Drugs Major Product Offerings
  6.4.4 Minoryx Sales and Revenue in South Korea (2015-2020)
  6.4.5 Minoryx Key News
6.5 MedDay Pharmaceuticals
  6.5.1 MedDay Pharmaceuticals Corporate Summary
  6.5.2 MedDay Pharmaceuticals Business Overview
  6.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Major Product Offerings
  6.5.4 MedDay Pharmaceuticals Sales and Revenue in South Korea (2015-2020)
  6.5.5 MedDay Pharmaceuticals Key News

7 ADRENOLEUKODYSTROPHY DRUGS PRODUCTION CAPACITY, EXPORT AND IMPORT ANALYSIS

7.1 Adrenoleukodystrophy Drugs Production Capacity and Value in South Korea, Situation Analysis and Prediction, 2015-2026
  7.1.1 South Korea Adrenoleukodystrophy Drugs Production Capacity, 2015-2026
  7.1.2 South Korea Adrenoleukodystrophy Drugs Production 2015-2026
  7.1.3 South Korea Adrenoleukodystrophy Drugs Production Value 2015-2026
7.2 Key Local Adrenoleukodystrophy Drugs Manufacturers in South Korea
  7.2.1 South Korea Key Local Adrenoleukodystrophy Drugs Manufacturers Production Capacity
  7.2.2 South Korea Key Local Adrenoleukodystrophy Drugs Manufacturers Production
  7.2.3 South Korea Key Local Adrenoleukodystrophy Drugs Manufacturers Production Value
  7.2.4 The Proportion of Adrenoleukodystrophy Drugs Production Sold in South Korea and Sold Other Than South Korea by Manufacturers
7.3 Adrenoleukodystrophy Drugs Export and Import in South Korea
  7.3.1 South Korea Adrenoleukodystrophy Drugs Export Market
  7.3.2 South Korea Adrenoleukodystrophy Drugs Source of Imports

8 COVID-19 IMPACT: KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

8.1 PESTLE Analysis for South Korea Adrenoleukodystrophy Drugs Market
8.2 Market Opportunities & Trends
8.3 Market Drivers
8.4 Market Restraints

9 COVID-19 IMPACT ON ADRENOLEUKODYSTROPHY DRUGS SUPPLY CHAIN ANALYSIS

9.1 Supply Chain Analysis
9.2 Upstream Market Analysis
9.3 Downstream and Clients Market Analysis
9.4 Marketing Channels Analysis
  9.4.1 Marketing Channels
  9.4.2 Adrenoleukodystrophy Drugs Distributors and Sales Agents in South Korea

10 CONCLUSION

11 APPENDIX

11.1 Note
11.2 Examples of Clients
11.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Adrenoleukodystrophy Drugs in South Korea
Table 2. Top Players in South Korea, Ranking by Revenue (2019)
Table 3. South Korea Adrenoleukodystrophy Drugs Revenue by Companies, (US$, Mn), 2015-2020
Table 4. South Korea Adrenoleukodystrophy Drugs Revenue Share by Companies, 2015-2020
Table 5. South Korea Adrenoleukodystrophy Drugs Sales by Companies, (K Units), 2015-2020
Table 6. South Korea Adrenoleukodystrophy Drugs Sales Share by Companies, 2015-2020
Table 7. Key Manufacturers Adrenoleukodystrophy Drugs Price (2015-2020) (US$/Unit)
Table 8. South Korea Manufacturers Adrenoleukodystrophy Drugs Product Type
Table 9. List of South Korea Tier 1 Adrenoleukodystrophy Drugs Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 10. List of South Korea Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 11. By Type - Adrenoleukodystrophy Drugs Revenue in South Korea (US$, Mn), 2015-2020
Table 12. By Type - Adrenoleukodystrophy Drugs Revenue in South Korea (US$, Mn), 2021-2026
Table 13. By Type - Adrenoleukodystrophy Drugs Sales in South Korea (K Units), 2015-2020
Table 14. By Type - Adrenoleukodystrophy Drugs Sales in South Korea (K Units), 2021-2026
Table 15. By Application - Adrenoleukodystrophy Drugs Revenue in South Korea, (US$, Mn), 2015-2020
Table 16. By Application - Adrenoleukodystrophy Drugs Revenue in South Korea, (US$, Mn), 2021-2026
Table 17. By Application - Adrenoleukodystrophy Drugs Sales in South Korea, (K Units), 2015-2020
Table 18. By Application - Adrenoleukodystrophy Drugs Sales in South Korea, (K Units), 2021-2026
Table 19. Bluebird Bio Inc Corporate Summary
Table 20. Bluebird Bio Inc Adrenoleukodystrophy Drugs Product Offerings
Table 21. Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 22. NeuroVia, Inc. Corporate Summary
Table 23. NeuroVia, Inc. Adrenoleukodystrophy Drugs Product Offerings
Table 24. NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 25. Orpheris, Inc. Corporate Summary
Table 26. Orpheris, Inc. Adrenoleukodystrophy Drugs Product Offerings
Table 27. Orpheris, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 28. Minoryx Corporate Summary
Table 29. Minoryx Adrenoleukodystrophy Drugs Product Offerings
Table 30. Minoryx Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 31. MedDay Pharmaceuticals Corporate Summary
Table 32. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product Offerings
Table 33. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2015-2020)
Table 34. Adrenoleukodystrophy Drugs Production Capacity (K Units) of Local Manufacturers in South Korea, 2015-2020
Table 35. Adrenoleukodystrophy Drugs Production (K Units) of Local Manufacturers in South Korea, 2015-2020
Table 36. South Korea Adrenoleukodystrophy Drugs Production Market Share of Local Manufacturers, 2015-2020
Table 37. Adrenoleukodystrophy Drugs Production Value (US$, Mn) of Local Manufacturers in South Korea, 2015-2020
Table 38. South Korea Adrenoleukodystrophy Drugs Production Value Market Share of Local Manufacturers, 2015-2020
Table 39. The Percentage of Adrenoleukodystrophy Drugs Production Sold in South Korea and Sold Other Than South Korea by Manufacturers
Table 40. The Percentage of Adrenoleukodystrophy Drugs Production Sold in South Korea and Sold Other Than South Korea by Manufacturers
Table 41. Dangeguojia Adrenoleukodystrophy Drugs Sales (Consumption), Production, Export and Import, 2015-2020
Table 42. Raw Materials and Suppliers
Table 43. Adrenoleukodystrophy Drugs Downstream Clients in South Korea
Table 44. Adrenoleukodystrophy Drugs Distributors and Sales Agents in South Korea

List Of Figures

LIST OF FIGURES

Figure 1. Adrenoleukodystrophy Drugs Segment by Type
Figure 2. Adrenoleukodystrophy Drugs Segment by Application
Figure 3. Dangeguojia Adrenoleukodystrophy Drugs Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Adrenoleukodystrophy Drugs Market Size in South Korea, (US$, Mn) & (K Units): 2020 VS 2026
Figure 6. South Korea Adrenoleukodystrophy Drugs Revenue, 2015-2026 (US$, Mn)
Figure 7. Adrenoleukodystrophy Drugs Sales in South Korea: 2015-2026 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Adrenoleukodystrophy Drugs Revenue in 2019
Figure 9. By Type - South Korea Adrenoleukodystrophy Drugs Incremental Growth, (US$, Mn), 2015-2026
Figure 10. By Type - South Korea Adrenoleukodystrophy Drugs Market Share, 2015-2020
Figure 11. By Type - South Korea Adrenoleukodystrophy Drugs Market Share, 2020-2026
Figure 12. By Type - South Korea Adrenoleukodystrophy Drugs Price (US$/Unit), 2015-2026
Figure 13. By Application - Adrenoleukodystrophy Drugs Revenue in South Korea (US$, Mn), 2020 & 2026
Figure 14. By Application - South Korea Adrenoleukodystrophy Drugs Market Share, 2015-2020
Figure 15. By Application - South Korea Adrenoleukodystrophy Drugs Market Share, 2020-2026
Figure 16. By Application -South Korea Adrenoleukodystrophy Drugs Price (US$/Unit), 2015-2026
Figure 17. South Korea Adrenoleukodystrophy Drugs Production Capacity (K Units), 2015-2026
Figure 18. South Korea Adrenoleukodystrophy Drugs Actual Output (K Units), 2015-2026
Figure 19. South Korea Adrenoleukodystrophy Drugs Production Value (US$, Mn), 2015-2026
Figure 20. The Percentage of South Korea Adrenoleukodystrophy Drugs Export Destination, 2019
Figure 21. The Source of Imports of South Korea Adrenoleukodystrophy Drugs, 2019
Figure 22. PEST Analysis for South Korea Adrenoleukodystrophy Drugs Market in 2020
Figure 23. Adrenoleukodystrophy Drugs Market Opportunities & Trends in South Korea
Figure 24. Adrenoleukodystrophy Drugs Market Drivers in South Korea
Figure 25. Adrenoleukodystrophy Drugs Market Restraints in South Korea
Figure 26. Adrenoleukodystrophy Drugs Industry Value Chain